Ayça Bilginoğlu1, Duygu Aydın2, Seyma Ozsoy3, Hatice Aygün3. 1. Department of Biophysics, Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey. draycabilginoglu@hotmail.com. 2. Department of Physiology, Turgut Özal University Faculty of Medicine, Ankara, Turkey. 3. Department of Physiology, Gaziosmanpaşa University Faculty of Medicine, Tokat, Turkey.
Abstract
OBJECTIVES: Adriamycin is one of the most widely used anticancer drugs. The major limiting factor of using this drug is the development of cardiotoxicity. However, melatonin (N-acetyl-5-methoxytryptamine) is a ubiquitous molecule as a good antioxidant that may protect the heart. We investigated whether or not pretreatment with melatonin can attenuate adriamycin-induced cardiotoxicity. STUDY DESIGN: All procedures and experiments were approved by the Animal Ethics Committee of Gazi Osman Paşa University (2012-HADYEK-022). Adult male Wistar-Albino rats were randomly divided into four groups, namely control (CON, n=7), melatonin (MEL, n=7), adriamycin (ADR, n=7), and adriamycin+melatonin (ADR+MEL, n=7) groups. Cardiotoxicity in rats was induced by adriamycin injection (cumulative dose: 18 mg/kg, intraperitoneal [i.p.]) at an interval of 24 hours (h) on the 5th, 6th and 7th days. Rats receiving melatonin treatment in the adriamycin group received melatonin (10 mg/kg/day, i.p.) for 7 days and were injected with adriamycin (18 mg/kg, i.p.) on 5th, 6th and 7th days. On the 8th day, gravimetric, electrocardiography (ECG) and biochemical parameters were assessed. RESULTS: Adriamycin induction caused changes in the ECG pattern, including ST-segment elevation and decreased R-amplitude, increase in the serum levels of cardiac injury markers (creatine kinase [CK], CK-MB, aspartate transaminase, and lactate dehydrogenase), decrease in the antioxidant enzymes activity (superoxide dismutase, glutathione peroxidase), elevated lipid peroxidation (malondialdehyde), and altered lipid profile in the serum. Melatonin treatment prevented all the parameters of adriamycin-induced cardiotoxicity in rats. CONCLUSION: Melatonin has a protective effect on the heart against adriamycin-induced cardiotoxicity in rats.
OBJECTIVES:Adriamycin is one of the most widely used anticancer drugs. The major limiting factor of using this drug is the development of cardiotoxicity. However, melatonin (N-acetyl-5-methoxytryptamine) is a ubiquitous molecule as a good antioxidant that may protect the heart. We investigated whether or not pretreatment with melatonin can attenuate adriamycin-induced cardiotoxicity. STUDY DESIGN: All procedures and experiments were approved by the Animal Ethics Committee of Gazi Osman Paşa University (2012-HADYEK-022). Adult male Wistar-Albino rats were randomly divided into four groups, namely control (CON, n=7), melatonin (MEL, n=7), adriamycin (ADR, n=7), and adriamycin+melatonin (ADR+MEL, n=7) groups. Cardiotoxicity in rats was induced by adriamycin injection (cumulative dose: 18 mg/kg, intraperitoneal [i.p.]) at an interval of 24 hours (h) on the 5th, 6th and 7th days. Rats receiving melatonin treatment in the adriamycin group received melatonin (10 mg/kg/day, i.p.) for 7 days and were injected with adriamycin (18 mg/kg, i.p.) on 5th, 6th and 7th days. On the 8th day, gravimetric, electrocardiography (ECG) and biochemical parameters were assessed. RESULTS:Adriamycin induction caused changes in the ECG pattern, including ST-segment elevation and decreased R-amplitude, increase in the serum levels of cardiac injury markers (creatine kinase [CK], CK-MB, aspartate transaminase, and lactate dehydrogenase), decrease in the antioxidant enzymes activity (superoxide dismutase, glutathione peroxidase), elevated lipid peroxidation (malondialdehyde), and altered lipid profile in the serum. Melatonin treatment prevented all the parameters of adriamycin-induced cardiotoxicity in rats. CONCLUSION:Melatonin has a protective effect on the heart against adriamycin-induced cardiotoxicity in rats.
Authors: Mohammad Tobeiha; Ameneh Jafari; Sara Fadaei; Seyed Mohammad Ali Mirazimi; Fatemeh Dashti; Atefeh Amiri; Haroon Khan; Zatollah Asemi; Russel J Reiter; Michael R Hamblin; Hamed Mirzaei Journal: Front Cardiovasc Med Date: 2022-06-20
Authors: Javier Palacios; José Miguel Fonseca; Fernando Ayavire; Felipe Salas; Mirko Ortiz; Juan Marcelo Sandoval; Julio Benites; Chukwuemeka R Nwokocha; Ewaldo Zavala; Adrián Paredes; Iván Barría; José Luis Vega; Fredi Cifuentes Journal: Oxid Med Cell Longev Date: 2018-07-26 Impact factor: 6.543